NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ottimo Pharma

Ottimo Pharma

Private
LondonHealthcare & Life Scienceshttps://ottimopharma.com/

Last Round

Series A

Dec 19, 2024

Total Funding Raised

$140M

Company Overview

Ottimo Pharma is a biotechnology company that develops pioneering bi-functional medicines and cancer therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodyoncologybi-functional antibodysolid tumorscancer immunotherapyclinical trialsdrug discoveryPD-1VEGFR-2biologicsantibody engineeringclinical-stage biotechangiogenesischeckpoint inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ottimo Pharma Comps

Public and private peers based on sector, stage, and business model.

Ottimo Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ottimo Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 19, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

David Epstein

Chairman & CEO

Executive Team

Ottimo Pharma Investors

Notable investors and investment history

Ottimo Pharma investors
InvestorRounds
Janus Henderson GroupSeries A
Avoro CapitalSeries A
OrbiMedSeries A
Invus OpportunitiesSeries A
J.P. Morgan Life Sciences Private CapitalSeries A
RTW InvestmentsSeries A
Samsara BioCapitalSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 27, 2025

    Partnered with Asimov for cell line development.

  • Jun 23, 2025

    Contract manufacturing agreement signed with LOTTE BIOLOGICS for antibody therapeutics.

View all signals

Ottimo Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ottimo Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ottimo Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range19
Year Founded2020
Last FundingDec 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.